Citation Impact
Citing Papers
Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases
2016 Standout
Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance.
2000
Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder
2004
Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar
2005
MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells
2000
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells
2002
Multidrug resistance (MDR) in cancer
2000
Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance
1995
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Therapeutic Drug Monitoring in Oncology
1987
Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line
1990
Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease
1993 Standout
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines
2001
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
New Therapeutic Options for Chemotherapy-Resistant Metastatic Breast Cancer
2008
Marine natural products
1990 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Head and neck cancer
2008 Standout
Nanoparticles in cancer therapy and diagnosis
2002 Standout
Escalating drug delivery in cancer chemotherapy: A review of concepts and practice —Part 2
1993
Principles of bioactive lipid signalling: lessons from sphingolipids
2008 Standout
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
2005
Curcumin as “Curecumin”: From kitchen to clinic
2007 Standout
Vascular Endothelial Growth Factor and Angiogenesis
2004 Standout
Clinical applications of quinone-containing alkylating agents
2000
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
1996 Standout
Molecular mechanisms of cisplatin resistance
2011 Standout
Quantitative Determination of Factors Contributing to Doxorubicin Resistance in Multidrug-Resistant Cells
1989
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Targeting multidrug resistance in cancer
2006 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers
2008
Chronic Health Conditions in Adult Survivors of Childhood Cancer
2006 Standout
Microfluidic organs-on-chips
2014 Standout
The pathobiology of mucositis
2004 Standout
Topoisomerase II Is Required for Mitoxantrone to Signal Nuclear Factor κB Activation in HL60 Cells
2000
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia
2001
Head and Neck Cancer
1993 Standout
A genetically engineered cell-based biosensor for functional classification of agents
2001 StandoutNobel
Protective mechanisms against the antitumor agent bleomycin: lessons from Saccharomyces cerevisiae
2003
Novel crosslinking methods to design hydrogels
2002 Standout
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2003 Standout
Microtubules as a target for anticancer drugs
2004 Standout
Predicting drug sensitivity and resistance
2004
Genetic Susceptibility to Head and Neck Cancer: Interaction Between Nutrition and Mutagen Sensitivity
1997
Drug discovery from medicinal plants
2005 Standout
Pulmonary Toxicity of Chemotherapy
2006
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Glycosphingolipids and drug resistance
2006
Multidrug-resistant Human Sarcoma Cells with a Mutant P-Glycoprotein, Altered Phenotype, and Resistance to Cyclosporins
1997
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers
2007
Curcumin: From ancient medicine to current clinical trials
2008 Standout
Late effects of childhood cancer therapy
2002
Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids
2004
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
N‐acyliminium intermediates in solid‐phase synthesis
2010 StandoutNobel
Animal models of acute lung injury
2008 Standout
Liposomal protection of adriamycin-induced cardiotoxicity in mice.
1980
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
2002
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
2012 Standout
Tumour stem cells and drug resistance
2005 Standout
Changing role of chemotherapy in treatment of head and neck cancer
1982
Drug delivery systems
1981
Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity
1986
MDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study
2000
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
1999 Standout
Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
1998
Doxorubicin selection for MDR1/P-glycoprotein reduces swelling-activated K+ and Cl- currents in MES-SA cells
1996
Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
2002
Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death
1999
Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
1987
Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization.
2004
Barrier properties of the newborn infant's skin
1983 Standout
Drug-induced pulmonary disease
1987
Mechanisms of Cancer Drug Resistance
2002 Standout
Functions of Ceramide in Coordinating Cellular Responses to Stress
1996 StandoutScience
Structure and expression of the human MDR (P-glycoprotein) gene family.
1989
Detection of Cell-Affecting Agents with a Silicon Biosensor
1989 Science
Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype.
2001
Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA.
1990
Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein.
1990
Design and Syntheses of Permethyl Ningalin B Analogues: Potent Multidrug Resistance (MDR) Reversal Agents of Cancer Cells
2010
Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine
2004
The Encapsulation of Bleomycin Within Chitosan Based Polymeric Vesicles Does Not Alter its Biodistribution
2000
A multidrug resistance transporter from human MCF-7 breast cancer cells
1998 Standout
Palladium‐Catalyzed Fluorosulfonylvinylation of Organic Iodides
2017 StandoutNobel
Functional Significance of Cell Volume Regulatory Mechanisms
1998 Standout
Drug Resistance in Cancer: An Overview
2014 Standout
Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity.
1983
Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature
2008 Standout
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
1992 StandoutScience
Bleomycin upregulates expression of γ-glutamylcysteine synthetase in pulmonary artery endothelial cells
2002
Works of Sikic Bi being referenced
Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model.
1992
Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model.
1992
Biochemical and cellular determinants of bleomycin cytotoxicity.
1986
Drug resistance in clinical oncology and hematology. Introduction.
1995
Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques.
1994
Modulation of multidrug resistance: a paradigm for translational clinical research.
1999
Pulmonary disease as a complication of chlorozotocin chemotherapy.
1981
Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA.
1985
Bleomycin, mitomycin, and cisplatin therapy for advanced squamous carcinoma of the uterine cervix: a phase II study of the Northern California Oncology Group.
1985
Improved therapeutic index of bleomycin when administered by continuous infusion in mice.
1978
Adsorption of antineoplastic drugs following large-volume ip administration to rats.
1982